Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
Oct 15, 2024 | Benefits preservation, Biosimilars, Cost Savings, Drug costs, High-cost claims, Rx Costs, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Feb 20, 2024 | Alternative Reimbursement Strategies, Announcements, Benchmarks, Benefits preservation, Fair market reimbursement, MedBen University, Pharmacogenomics, Precision medicine, Roundtables, Specialty Drugs, Trend
MedBen University (MBU) is in session, so mark your calendar! As we mentioned in the last e-briefs, MBU launched its 23rd season last month with the Benefits Advisory Conference for brokers… and this Spring, MBU will be conducting two employer roundtables:...
Feb 6, 2024 | Claims, Claims data, Cost Savings, Drug costs, Gene therapy, Genetic testing, MedBen News, MedBen Rx, MedBen University, Pharmacogenics, Pharmacy Benefits Manager (PBM), Self-funding, Specialty Drugs, Stop-Loss
MedBen recently had the honor to welcome some of the most respected names in the benefits management industry. At the invitation-only 2024 Benefits Advisory Conference on January 26, attending brokers learned about health plan innovations that will help self-funded...
Jan 22, 2024 | Access solutions, Benefits preservation, MedBen Rx, Pharmacy, Prescription, Specialty Drugs
A recent Segal Health Plan Cost Trend Survey projects 2024 cost trend for prescription drugs to approach 10%… but specialty drug trend alone may reach 15% this year, as increased use of expensive drugs continues to drive costs up. (We’ve actually seen...
Aug 7, 2023 | Access solutions, Case Studies, Cost Savings, Drug costs, Limited use HRA, MedBen Rx, Patient advocacy program, Pharmacy, Rx Costs, Savings, Specialty Drugs
With specialty drugs now making up about half of total drug spending – and poised to go even higher as more new specialty drugs roll out every year – the need for workable access solutions grows. Fortunately, MedBen Rx has them. Our unique approach incorporates a...
